Oxford Biodynamics
Oxford Biodynamics Limited (OBD) is a UK-based Company with a patented biomarker discovery platform EpiSwitch™. The platform enables monitoring of epigenetic gene regulation and associated chromosome conformation signatures. Aberrant epigenetic changes within those signatures have been implicated in different diseases/disorders including oncology, metabolic and auto-immune disorders as well as neurodegenerative and age-related diseases.
History
OBD was founded in April 2007 as a Limited Company in England and Wales by former scientists of the University of Oxford. The Company's headquarters and reference laboratory are based in Oxford, UK. In 2015, OBD opened its new subsidiary, Oxford Biodynamics (M) SDB BHD in Penang, Malaysia.
Technology
The technology has been used to develop epigenetically based diagnostic, prognostic and predictive stratifications from whole blood, cell lines and primary cells. The platform can be combined with other sequencing platforms or other DNA detection methods. The technology is ISO13485 and ISO9001 compliant.
Global Partnerships
* The Nuffield Department of Clinical Neurosciences (Oxford University) and Chronos Therapeutics Limited, UK
* Nova Satra Health, Malaysian Healthcare Investment Group, South East Asia
* The Genome Institute of Singapore (GIS), Singapore
History
OBD was founded in April 2007 as a Limited Company in England and Wales by former scientists of the University of Oxford. The Company's headquarters and reference laboratory are based in Oxford, UK. In 2015, OBD opened its new subsidiary, Oxford Biodynamics (M) SDB BHD in Penang, Malaysia.
Technology
The technology has been used to develop epigenetically based diagnostic, prognostic and predictive stratifications from whole blood, cell lines and primary cells. The platform can be combined with other sequencing platforms or other DNA detection methods. The technology is ISO13485 and ISO9001 compliant.
Global Partnerships
* The Nuffield Department of Clinical Neurosciences (Oxford University) and Chronos Therapeutics Limited, UK
* Nova Satra Health, Malaysian Healthcare Investment Group, South East Asia
* The Genome Institute of Singapore (GIS), Singapore
Comments